Cassandra, Chicken Little, and Public Policy for Start-Ups
Executive Summary
Given the drastic investment situation for health care start-ups, it's time for some modest government rule changes: bring back tax-advantaged R&D partnerships; let biotechs and small device companies sell their net operating losses; set up clear rules for accounting for purchased R&D.
You may also be interested in...
FDA Details Alternatives For COVID-19 Test Supplies
The US agency has released a document explaining what COVID-19 testing supplies may be substituted.
Curecumin Piques US Consumers’ Interest; UK Curiosity Grows For Omega-3, Survey Shows
Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.
AstraZeneca Links With Accent To Target RNA-Modifying Proteins
AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.
Need a specific report? 1000+ reports available
Buy Reports